Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Opioid-Induced Constipation

• Colonic Motor Patterns in Healthy Volunteers
• Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
• Prevention of Opioid-induced Constipation in Patients With Metastatic Cancer
• Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
• Use of MgSO4 for Pain After Bariatric Surgery
• Naloxegol and Opioid-induced Constipation
• Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
• To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
• Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
• Naloxegol Health Outcome Post Authorisation Safety Study
• Naloxegol US PMR CV Safety.
• Naloxegol Drug Utilization PASS
• Naloxegol in Cancer Opioid-Induced Constipation
• Study of Methylnaltrexone in Opioid-Induced Constipation Patients
• Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery
• Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section
• Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
• Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation
• Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
• Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)
• Long Term Safety of Naldemedine
• Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
• A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).
• The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
• Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
• Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
• Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
• Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol
• A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
• A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
• A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
• Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain
• ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
• A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
• A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
• Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
• ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
• Compassionate Use Study of Methylnaltrexone
• Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
• Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
• A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation
• Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
• Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
• Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
• Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
• Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
• Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
• A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
• Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
• Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
• A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
• ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
• Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit
• A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
• Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients
• Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
• Naloxone SR Capsules in Patients With Opioid Induced Constipation
• Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation
• Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
• Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
• Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
• Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
• Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation
• Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
• Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
• A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)
• Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
• Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
• Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
• Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
• A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
• Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
• Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain
• Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
• Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects